JP5778168B2 - 多環式化合物及びその使用方法 - Google Patents

多環式化合物及びその使用方法 Download PDF

Info

Publication number
JP5778168B2
JP5778168B2 JP2012542219A JP2012542219A JP5778168B2 JP 5778168 B2 JP5778168 B2 JP 5778168B2 JP 2012542219 A JP2012542219 A JP 2012542219A JP 2012542219 A JP2012542219 A JP 2012542219A JP 5778168 B2 JP5778168 B2 JP 5778168B2
Authority
JP
Japan
Prior art keywords
disorder
optionally substituted
compound
synthesis
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012542219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013512926A (ja
JP2013512926A5 (OSRAM
Inventor
シャオ ルイミング
シャオ ルイミング
エムメルソン カムプベルル ジョフン
エムメルソン カムプベルル ジョフン
チャルレス ヘウイトト ミチャエル
チャルレス ヘウイトト ミチャエル
カムプベルル ウナ
カムプベルル ウナ
ジー．ハナニア タルエエン
ジー．ハナニア タルエエン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Psychogenics Inc
Original Assignee
Psychogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psychogenics Inc filed Critical Psychogenics Inc
Publication of JP2013512926A publication Critical patent/JP2013512926A/ja
Publication of JP2013512926A5 publication Critical patent/JP2013512926A5/ja
Application granted granted Critical
Publication of JP5778168B2 publication Critical patent/JP5778168B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2012542219A 2009-12-04 2010-12-03 多環式化合物及びその使用方法 Active JP5778168B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26688009P 2009-12-04 2009-12-04
US61/266,880 2009-12-04
PCT/US2010/058884 WO2011069063A2 (en) 2009-12-04 2010-12-03 Multicyclic compounds and methods of use thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2014253082A Division JP5710064B1 (ja) 2009-12-04 2014-12-15 多環式化合物及びその使用方法
JP2015136603A Division JP6005807B2 (ja) 2009-12-04 2015-07-08 多環式化合物及びその使用方法

Publications (3)

Publication Number Publication Date
JP2013512926A JP2013512926A (ja) 2013-04-18
JP2013512926A5 JP2013512926A5 (OSRAM) 2014-01-23
JP5778168B2 true JP5778168B2 (ja) 2015-09-16

Family

ID=44115515

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2012542219A Active JP5778168B2 (ja) 2009-12-04 2010-12-03 多環式化合物及びその使用方法
JP2014253082A Active JP5710064B1 (ja) 2009-12-04 2014-12-15 多環式化合物及びその使用方法
JP2015136603A Active JP6005807B2 (ja) 2009-12-04 2015-07-08 多環式化合物及びその使用方法
JP2016131247A Active JP6028310B1 (ja) 2009-12-04 2016-07-01 多環式化合物及びその使用方法
JP2016191898A Active JP6297655B2 (ja) 2009-12-04 2016-09-29 多環式化合物及びその使用方法
JP2018028819A Pending JP2018104454A (ja) 2009-12-04 2018-02-21 多環式化合物及びその使用方法
JP2020108727A Active JP7104746B2 (ja) 2009-12-04 2020-06-24 多環式化合物及びその使用方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2014253082A Active JP5710064B1 (ja) 2009-12-04 2014-12-15 多環式化合物及びその使用方法
JP2015136603A Active JP6005807B2 (ja) 2009-12-04 2015-07-08 多環式化合物及びその使用方法
JP2016131247A Active JP6028310B1 (ja) 2009-12-04 2016-07-01 多環式化合物及びその使用方法
JP2016191898A Active JP6297655B2 (ja) 2009-12-04 2016-09-29 多環式化合物及びその使用方法
JP2018028819A Pending JP2018104454A (ja) 2009-12-04 2018-02-21 多環式化合物及びその使用方法
JP2020108727A Active JP7104746B2 (ja) 2009-12-04 2020-06-24 多環式化合物及びその使用方法

Country Status (20)

Country Link
US (8) US8710245B2 (OSRAM)
EP (2) EP2507245B1 (OSRAM)
JP (7) JP5778168B2 (OSRAM)
KR (7) KR101855471B1 (OSRAM)
CN (5) CN104193761B (OSRAM)
AU (3) AU2010325925B2 (OSRAM)
BR (2) BR122021013836B1 (OSRAM)
CA (2) CA2781716A1 (OSRAM)
DK (2) DK3252057T3 (OSRAM)
ES (2) ES2625330T3 (OSRAM)
FI (1) FI3252057T3 (OSRAM)
HK (1) HK1212969A1 (OSRAM)
IL (6) IL272376B2 (OSRAM)
MX (3) MX388468B (OSRAM)
NZ (5) NZ767139A (OSRAM)
PT (2) PT2507245T (OSRAM)
RU (3) RU2707067C2 (OSRAM)
SG (3) SG181498A1 (OSRAM)
WO (1) WO2011069063A2 (OSRAM)
ZA (1) ZA201203533B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015227348A (ja) * 2009-12-04 2015-12-17 スノビオン プハルマセウトイカルス インコーポレイテッド 多環式化合物及びその使用方法

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066152A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
US10189825B2 (en) * 2012-02-08 2019-01-29 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
CN103755727B (zh) * 2013-12-20 2015-12-30 南京华威医药科技开发有限公司 布林佐胺中间体制备方法
WO2015112902A2 (en) * 2014-01-23 2015-07-30 Sova Pharmaceuticals, Inc. CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN
MA40530A (fr) 2014-08-27 2017-07-05 Prexton Therapeutics Sa Nouveau dérivé d'oxime de chromone et son utilisation comme modulateur allostérique de récepteurs métabotropiques du glutamate
CN104193722A (zh) * 2014-08-27 2014-12-10 湖南华腾制药有限公司 一种n-叔丁氧羰基-3-甲胺噻吩的制备方法
EA201791804A1 (ru) * 2015-02-11 2018-02-28 Суновион Фармасьютикалз Инк. Соединения 1-гетероциклил изохроманила и аналоги для лечения расстройств цнс
CN107567454B (zh) * 2015-02-11 2020-02-18 赛诺维信制药公司 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物及其类似物
SI3341380T1 (sl) 2015-08-27 2020-02-28 Prexton Therapeutics Sa Možgansko-penetranten derivat kromon oksima za terapijo levodopa-inducirane diskinezije
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
PL3838274T3 (pl) * 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
WO2017144341A1 (de) 2016-02-23 2017-08-31 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
US10196403B2 (en) 2016-07-29 2019-02-05 Sunovion Pharmaceuticals Inc. Compounds and compositions and uses thereof
KR20190065246A (ko) 2016-07-29 2019-06-11 선오비온 파마슈티컬스 인코포레이티드 화합물 및 조성물 및 이들의 용도
WO2018151861A1 (en) * 2017-02-16 2018-08-23 Sunovion Pharamaceuticials Inc. Methods of treating schizophrenia
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
US20210008030A1 (en) * 2018-02-16 2021-01-14 Sunovion Pharmaceuticals Inc. Methods of treating social function disorders
EP3752508A1 (en) * 2018-02-16 2020-12-23 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
US20200179336A1 (en) * 2018-12-06 2020-06-11 Sunovion Pharmaceuticals Inc. Methods of treating neurological and psychiatric disorders
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
CN110894195A (zh) * 2019-12-09 2020-03-20 门希国 一种新的2-噻吩乙酸的制备新方法
EP4125840A1 (en) 2020-03-27 2023-02-08 Som Innovation Biotech, S.A. Compounds for use in the treatment of synucleinopathies
WO2021211489A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
EP4214212A1 (en) 2020-09-16 2023-07-26 Teva Pharmaceuticals International GmbH Solid state forms of sep-363856 and process for preparation thereof
JP7624092B2 (ja) * 2021-03-29 2025-01-29 シューチン バイオファーマ カンパニー リミテッド スピロ環含有誘導体、その調製方法及び使用
US12077546B2 (en) 2021-04-10 2024-09-03 Sumitomo Pharma Co., Ltd. Bicyclic pyridine derivative
KR20230169218A (ko) * 2021-04-10 2023-12-15 스미토모 파마 가부시키가이샤 2환성 피리딘 유도체
CN117177977A (zh) * 2021-04-10 2023-12-05 住友制药株式会社 二环吡啶衍生物
CN115677718B (zh) * 2021-07-30 2024-11-01 武汉思瓴生物科技有限公司 甲基甲胺类衍生物制剂、药物组合物及其应用
US20230241024A1 (en) 2021-09-23 2023-08-03 Sunovion Pharmaceuticals Inc. Methods of treating metabolic disorders
JP2024542057A (ja) 2021-11-04 2024-11-13 シャンハイ ハンソー バイオメディカル カンパニー リミテッド ２－（アリール－２－イル）モルホリンとその重水素化誘導体、製造方法及び応用
CN114324369B (zh) * 2022-03-11 2022-06-07 北京新研创能科技有限公司 双极板表面划痕检测系统及方法
JP2025525370A (ja) * 2022-06-24 2025-08-05 シャンドン ルイ ファーマシューティカル カンパニー リミテッド Ｔａａｒ１リガンドアゴニストとしての複素環式化合物
AU2023334027A1 (en) 2022-08-30 2025-01-09 Sumitomo Pharma America, Inc. Ulotaront for the adjuvant treatment of major depressive disorder
TWI891070B (zh) * 2022-09-27 2025-07-21 大陸商上海樞境生物科技有限公司 一種含螺環類衍生物的鹽、晶型及其製備方法和應用
JP2025534727A (ja) 2022-10-13 2025-10-17 スミトモ・ファーマ・アメリカ・インコーポレイテッド 精神神経治療に対する身体的依存を軽減する方法
CN115677719B (zh) * 2022-10-27 2025-03-07 复旦大学 一种芳基并杂环化合物及其制备方法和用途
TW202421114A (zh) 2022-10-28 2024-06-01 美商住友製藥美國公司 治療焦慮及相關病狀之方法
KR20250105660A (ko) 2022-11-15 2025-07-08 스미토모 파마 아메리카, 인크. 울로타론트를 이용한 신경정신 약물 변경 방법
CN120418254A (zh) * 2022-12-09 2025-08-01 上海枢境生物科技有限公司 并环类衍生物、其制备方法、中间体和应用
WO2025097104A1 (en) * 2023-11-02 2025-05-08 Pgi Drug Discovery Llc Thienyl compounds for the treatment of a central nervous system disease or disorder
WO2025131045A1 (zh) * 2023-12-22 2025-06-26 山东绿叶制药有限公司 一种taar1配体激动剂的盐型、晶型及其制备方法和应用
US20250262185A1 (en) 2024-02-16 2025-08-21 Sumitomo Pharma America, Inc. Methods of administering neuropsychiatric medications based on renal impairment
WO2025179091A2 (en) 2024-02-23 2025-08-28 Sumitomo Pharma America, Inc. Ulotaront hydrochloride manufacturing process

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US402145A (en) * 1889-04-30 Combined trough and rack
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4036842A (en) 1972-05-16 1977-07-19 American Home Products Corporation Process for preparing polycyclic heterocycles having a pyran ring
US4021451A (en) * 1972-05-16 1977-05-03 American Home Products Corporation Process for preparing polycyclic heterocycles having a pyran ring
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4021452A (en) 1975-04-23 1977-05-03 American Cyanamid Company 2,5-Dihydro-2,5-dialkoxyfuran derivatives
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4127665A (en) 1978-01-18 1978-11-28 Pfizer Inc. Thienohydantoin derivatives
US4147797A (en) * 1978-08-11 1979-04-03 Pfizer Inc. Spiro-furanohydantoin derivatives
FR2459239A1 (fr) * 1979-06-20 1981-01-09 Logeais Labor Jacques Nouveaux derives amines du benzothiazole, leur procede de preparation et leur application en therapeutique
GB8333512D0 (en) * 1983-12-16 1984-01-25 Erba Farmitalia Tetrahydropyrano derivatives
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
NZ219646A (en) * 1986-03-27 1990-10-26 Merck Sharp & Dohme Oxadiazole derivatives of azacyclics for treating cns disorders
PH30676A (en) * 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
DE68923891T2 (de) 1988-03-16 1996-02-22 Smithkline Beecham Farm Heterocyclische Derivate.
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
DE3827727A1 (de) 1988-08-16 1990-02-22 Boehringer Ingelheim Kg Anellierte tetrahydropyridinessigsaeurederivate, verfahren zu deren herstellung und verwendung solcher verbindungen zur kardioprotektion
GB8824400D0 (en) 1988-10-18 1988-11-23 Glaxo Group Ltd Chemical compounds
EP0368175A1 (de) 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
GB8827479D0 (en) 1988-11-24 1988-12-29 Zambeletti Spa L Novel compounds
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
EP0416740A3 (en) 1989-08-08 1991-08-28 Beecham Group P.L.C. Novel compounds with renin-inhibiting activity
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
GB8926560D0 (en) 1989-11-24 1990-01-17 Zambeletti Spa L Pharmaceuticals
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
GB8927872D0 (en) 1989-12-08 1990-02-14 Beecham Group Plc Pharmaceuticals
JPH03223277A (ja) * 1989-12-29 1991-10-02 Yoshitomi Pharmaceut Ind Ltd ベンゾチオフェン誘導体
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
ZA912744B (en) 1990-03-23 1992-02-26 Zambeletti Spa L Pharmaceuticals
JPH049367A (ja) 1990-04-26 1992-01-14 Zeria Pharmaceut Co Ltd アリールアルカノイル誘導体，該化合物の製造中間体及びそれらを含有する医薬
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
GB9018139D0 (en) 1990-08-17 1990-10-03 Pfizer Ltd Therapeutic agents
NZ240155A (en) 1990-10-29 1992-10-28 Ishihara Sangyo Kaisha Heterocyclyl acyl and (hexahydro) indanyl acyl substituted hydrazine derivatives, preparation thereof and pesticidal compositions
DE4104257A1 (de) 1991-02-13 1992-08-20 Boehringer Ingelheim Kg Verwendung von anellierten tetrahydropyridinessigsaeurederivaten fuer die behandlung neurologischer erkrankungen
GB9104839D0 (en) 1991-03-07 1991-04-17 Zambeletti Spa L Novel compounds
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
PH31294A (en) 1992-02-13 1998-07-06 Thomae Gmbh Dr K Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them.
JP3223277B2 (ja) 1992-04-10 2001-10-29 カシオ計算機株式会社 楽音制御装置
FR2692264B1 (fr) 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
IT1255178B (it) 1992-06-26 1995-10-20 Pierrel Spa N(eter0)-aril-n(etero)-tetralinalchil piperazine aventi attivita' serotoninergica,dopaminergica e adrenergica
DE59308842D1 (de) 1992-12-02 1998-09-10 Ciba Geigy Ag Selektiv-herbizides Mittel
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
TW334423B (en) * 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
JP3163068B2 (ja) 1993-12-27 2001-05-08 日本建工株式会社 野縁取付け金具
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2723091B1 (fr) 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
CN1300291A (zh) * 1998-03-12 2001-06-20 诺沃挪第克公司 蛋白质酪氨酸磷酸酶(ptp酶)的调节物
WO1999046267A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
EP1080068A1 (en) * 1998-03-12 2001-03-07 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
EP1123292A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
KR20010086104A (ko) 1998-12-14 2001-09-07 후지야마 아키라 피페라진 유도체
DE60028538T2 (de) 1999-01-19 2007-06-21 Neurosearch A/S Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
US6313309B1 (en) * 1999-04-05 2001-11-06 Ortho-Mcneil Pharmaceutical, Inc. 4-thionaphthyl—1H—imidazoles which are usefulα22-adrenoceptoR agonists/ antagonists
AU4589800A (en) 1999-05-05 2000-11-21 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7inhibitors
MXPA02000170A (es) 1999-07-02 2002-07-02 Warner Lambert Co Una combinacion sinergica: gabapentin y pregablin.
ATE309250T1 (de) * 1999-09-10 2005-11-15 Novo Nordisk As Modulatoren der protein tyrosin phosphatase (ptpases)
AU7476800A (en) 1999-09-10 2001-04-10 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
WO2001032610A1 (en) 1999-10-29 2001-05-10 Kaken Pharmaceutical Co., Ltd. Urea derivative, process for producing the same, and medicine containing the urea derivative
AR030537A1 (es) 1999-11-05 2003-08-27 Abbott Lab Acidos quinolincarboxilicos y naftiridincarboxilico antibacterianos
ATE253918T1 (de) * 1999-12-08 2003-11-15 Centre Nat Rech Scient Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
AU2001277731A1 (en) 2000-08-09 2002-02-18 Welfide Corporation Fused bicyclic amide compounds and medicinal use thereof
AU2001286191A1 (en) 2000-09-12 2002-03-26 Sankyo Company, Limited Quinolizine derivatives
WO2002102387A1 (en) 2001-06-18 2002-12-27 H. Lundbeck A/S Treatment of neuropathic pain
DE60202296D1 (de) * 2001-07-11 2005-01-20 Lilly Co Eli Pharmazeutische verbindungen mit serotonin rezeptor aktivität
WO2003006455A1 (en) 2001-07-11 2003-01-23 Eli Lilly And Company Pharmaceutical compounds with serotonin receptor activity
MXPA04003954A (es) 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.
JP2003261566A (ja) 2002-03-11 2003-09-19 Sankyo Co Ltd キノリジンを含有する医薬
TW200306783A (en) * 2002-04-29 2003-12-01 Fmc Corp Pesticidal heterocycles
US7358269B2 (en) 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US7323485B2 (en) 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7276522B2 (en) 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
SE0202134D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
MXPA05004033A (es) 2002-10-16 2005-06-08 Isis Innovation Hidroxilasas de asparaginil y moduladores de las mismas.
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
KR100678800B1 (ko) * 2002-11-21 2007-02-05 화이자 프로덕츠 인코포레이티드 3-아미노-피페리딘 유도체 및 그의 제조 방법
WO2004066912A2 (en) 2003-01-31 2004-08-12 Technion Research & Development Foundation Ltd. Anti-inflammatory compositions and uses thereof
EP2527326B1 (en) 2003-03-07 2014-10-08 Santen Pharmaceutical Co., Ltd Novel compounds having 4-pyridylalkylthio group as substituent
JP2004269449A (ja) 2003-03-11 2004-09-30 Ishihara Sangyo Kaisha Ltd ベンズアミド誘導体、それらの製造方法及びそれらを含有する有害生物防除剤
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
CN100475793C (zh) 2003-03-31 2009-04-08 大正制药株式会社 喹唑啉衍生物及其制备药物的用途
JP2005145859A (ja) 2003-11-13 2005-06-09 Nippon Steel Chem Co Ltd 脱水素化方法及び芳香族複素環化合物の製造方法
DE10360793A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
AU2005208938A1 (en) 2004-01-29 2005-08-11 Elixir Pharmaceuticals, Inc Anti-viral therapeutics
DE102004004974A1 (de) 2004-01-31 2005-08-18 Aventis Pharma Deutschland Gmbh Thieno-Iminosäure-Derivate als Inhibitoren von Matrix-Metalloproteinasen
KR100553398B1 (ko) 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
AU2005267798A1 (en) 2004-07-28 2006-02-09 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
SE0401970D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Novel compounds
EP1634873A1 (en) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
FR2875230A1 (fr) 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
JP2006117568A (ja) 2004-10-20 2006-05-11 Mitsubishi Pharma Corp チオフェン環を有する新規アミド誘導体及びその医薬としての用途
WO2006053274A2 (en) 2004-11-15 2006-05-18 Bristol-Myers Squibb Company 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
TW200640931A (en) 2005-02-17 2006-12-01 Wyeth Corp Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
CA2605594A1 (en) 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited Heterocyclic compound
WO2007001939A1 (en) 2005-06-27 2007-01-04 Janssen Pharmaceutica N.V. Tetrahydro-pyranopyrazole compounds displaying cannabinoid modulating activities
KR20080030630A (ko) 2005-06-27 2008-04-04 이 아이 듀폰 디 네모아 앤드 캄파니 전기 전도성 중합체 조성물
BRPI0615524A2 (pt) 2005-07-11 2010-04-06 Devgen Nv derivados da amida como inibidores da quinase
WO2007095586A2 (en) 2006-02-14 2007-08-23 The Trustees Of Columbia University In The City Of New York Neuronal pain pathway modulators
JP2009528999A (ja) 2006-02-21 2009-08-13 アンプラ ファーマシューティカルズ インコーポレイテッド Ｃｂ１アンタゴニストおよび逆アゴニスト
EP1829869A1 (en) * 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands
JPWO2007126041A1 (ja) * 2006-04-28 2009-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンゾイソオキサゾール化合物
WO2008042422A2 (en) 2006-10-04 2008-04-10 Schering Corporation Bicyclic and tricyclic derivatives as thrombin receptor antagonists
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2008058342A1 (en) 2006-11-15 2008-05-22 Genetic Technologies Limited Compounds, compositions and methods for controlling invertebrate pests
WO2009008906A2 (en) 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Therapeutic compounds for blocking dna synthesis of pox viruses
US7598417B2 (en) 2007-04-12 2009-10-06 Allergan, Inc. Substituted fluoroethyl ureas as alpha 2 adrenergic agents
EP1982987A1 (en) * 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Spiro-pyrano-pyrazole derivatives
EP1982714A1 (en) * 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
EP2020414A1 (en) * 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
US8338623B2 (en) * 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
CA2706391A1 (en) 2007-11-21 2009-05-28 Janssen Pharmaceutica N.V. Spiropiperidines for use as tryptase inhibitors
US7973051B2 (en) 2007-11-30 2011-07-05 Hoffman-La Roche Inc. Aminothiazoles as FBPase inhibitors for diabetes
JPWO2009072621A1 (ja) 2007-12-07 2011-04-28 日産化学工業株式会社 置換ジヒドロアゾール化合物及び有害生物防除剤
WO2009085256A1 (en) 2007-12-27 2009-07-09 Panacos Pharmaceuticals, Inc. Anti-hiv compounds
CN101759710B (zh) 2008-10-06 2011-10-05 山东轩竹医药科技有限公司 含有取代的氮杂环的头孢菌素衍生物
US9776963B2 (en) 2008-11-10 2017-10-03 The Trustees Of The University Of Pennsylvania Small molecule CD4 mimetics and uses thereof
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
WO2011036889A1 (ja) 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
SI2501704T1 (sl) * 2009-11-16 2013-11-29 Eli Lilly Company Spojine spiropiperidina kot antagonisti oral-1 receptorja
NZ767139A (en) 2009-12-04 2022-08-26 Sunovion Pharmaceuticals Inc Multicyclic compounds and methods of use thereof
ES2610248T3 (es) 2009-12-28 2017-04-26 General Incorporated Association Pharma Valley Project Supporting Organisation Compuesto de 1,3,4-oxadiazol-2-carboxamida
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
EP2560636A4 (en) 2010-04-23 2013-11-27 Kineta Inc ANTIVIRAL CONNECTIONS
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8569339B2 (en) 2011-03-10 2013-10-29 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
CN102731574B (zh) 2011-03-30 2016-03-02 中国人民解放军军事医学科学院毒物药物研究所 噻吩并吡啶类α-胺基苄基膦酸酯、其制备方法及用途
WO2013010453A1 (en) 2011-07-15 2013-01-24 Abbott Laboratories Chemoking receptor antagonists
WO2016013475A1 (ja) 2014-07-23 2016-01-28 シャープ株式会社 表示装置およびその駆動方法
WO2018151861A1 (en) 2017-02-16 2018-08-23 Sunovion Pharamaceuticials Inc. Methods of treating schizophrenia
EP3752508A1 (en) 2018-02-16 2020-12-23 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
US20210008030A1 (en) 2018-02-16 2021-01-14 Sunovion Pharmaceuticals Inc. Methods of treating social function disorders
US20200179336A1 (en) 2018-12-06 2020-06-11 Sunovion Pharmaceuticals Inc. Methods of treating neurological and psychiatric disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015227348A (ja) * 2009-12-04 2015-12-17 スノビオン プハルマセウトイカルス インコーポレイテッド 多環式化合物及びその使用方法

Also Published As

Publication number Publication date
JP5710064B1 (ja) 2015-04-30
CN102762575A (zh) 2012-10-31
US10894033B2 (en) 2021-01-19
FI3252057T3 (fi) 2024-06-20
NZ767139A (en) 2022-08-26
RU2557059C2 (ru) 2015-07-20
AU2016200448B2 (en) 2017-11-09
US9351954B2 (en) 2016-05-31
KR20170100047A (ko) 2017-09-01
US20160083399A1 (en) 2016-03-24
AU2017248551B2 (en) 2019-07-11
MX388468B (es) 2025-03-20
IL243015B (en) 2018-10-31
SG10201401661RA (en) 2014-07-30
PT3252057T (pt) 2024-06-04
BR112012013431B1 (pt) 2022-04-12
AU2010325925A1 (en) 2012-06-07
RU2707067C2 (ru) 2019-11-22
IL272376A (en) 2020-03-31
RU2012127770A (ru) 2014-01-10
KR20180049235A (ko) 2018-05-10
US10085968B2 (en) 2018-10-02
JP2015227348A (ja) 2015-12-17
KR101855471B1 (ko) 2018-05-09
KR20210120133A (ko) 2021-10-06
RU2018100098A3 (OSRAM) 2019-07-17
MX2020012825A (es) 2021-02-17
IL243018B (en) 2020-05-31
DK3252057T3 (da) 2024-06-17
JP2016196497A (ja) 2016-11-24
NZ731621A (en) 2019-01-25
CN106883246B (zh) 2020-05-29
BR122021013836B1 (pt) 2022-05-24
AU2016200448C1 (en) 2018-05-10
NZ600008A (en) 2014-10-31
CN106883246A (zh) 2017-06-23
JP6005807B2 (ja) 2016-10-12
KR101637246B1 (ko) 2016-07-07
KR20200013071A (ko) 2020-02-05
EP3252057B1 (en) 2024-03-27
EP2507245B1 (en) 2017-04-12
KR102307413B1 (ko) 2021-10-01
US20200323819A1 (en) 2020-10-15
US20130109677A1 (en) 2013-05-02
IL243019B (en) 2018-08-30
KR101772834B1 (ko) 2017-08-29
EP2507245A4 (en) 2013-05-01
HK1212969A1 (zh) 2016-06-24
ES2625330T3 (es) 2017-07-19
JP2015091833A (ja) 2015-05-14
US20220387382A1 (en) 2022-12-08
JP2018104454A (ja) 2018-07-05
JP6297655B2 (ja) 2018-03-20
CN104193761B (zh) 2017-10-17
AU2010325925B2 (en) 2016-02-25
AU2017248551A1 (en) 2017-11-09
RU2641648C1 (ru) 2018-01-19
RU2018100098A (ru) 2019-07-09
JP2013512926A (ja) 2013-04-18
US20240358675A1 (en) 2024-10-31
IL272376B1 (en) 2024-03-01
JP7104746B2 (ja) 2022-07-21
CA2781716A1 (en) 2011-06-09
WO2011069063A2 (en) 2011-06-09
ZA201203533B (en) 2013-08-28
WO2011069063A3 (en) 2011-10-20
KR20120127581A (ko) 2012-11-22
NZ748531A (en) 2020-09-25
US20190125722A1 (en) 2019-05-02
KR102505085B1 (ko) 2023-02-28
JP2020164541A (ja) 2020-10-08
EP3252057A2 (en) 2017-12-06
BR112012013431A2 (pt) 2016-04-05
CN118165002A (zh) 2024-06-11
US20140256712A1 (en) 2014-09-11
SG10201510665WA (en) 2016-01-28
NZ711802A (en) 2017-06-30
EP2507245A2 (en) 2012-10-10
KR101637247B1 (ko) 2016-07-07
CA3272595A1 (en) 2025-10-30
PT2507245T (pt) 2017-05-22
KR20150090269A (ko) 2015-08-05
KR102074089B1 (ko) 2020-02-05
NZ626068A (en) 2016-06-24
EP3252057A3 (en) 2018-02-21
IL220173A0 (en) 2012-07-31
ES2978959T3 (es) 2024-09-23
IL243021B (en) 2018-04-30
DK2507245T3 (en) 2017-05-22
JP6028310B1 (ja) 2016-11-16
BR112012013431A8 (pt) 2017-12-26
CN104193761A (zh) 2014-12-10
US8710245B2 (en) 2014-04-29
KR20160083136A (ko) 2016-07-11
AU2016200448A1 (en) 2016-02-18
CN102762575B (zh) 2015-04-15
MX2012006326A (es) 2012-10-09
SG181498A1 (en) 2012-07-30
IL272376B2 (en) 2024-07-01
CN111560025A (zh) 2020-08-21
JP2017031198A (ja) 2017-02-09
HK1247911A1 (en) 2018-10-05
US20210267938A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
JP7104746B2 (ja) 多環式化合物及びその使用方法
HK40035246A (en) Multicyclic compounds and methods of use thereof
HK1175774B (zh) 多環化合物及其使用方法
HK1247911B (en) Multicyclic compounds and methods of use thereof
HK1175774A (en) Multicyclic compounds and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150708

R150 Certificate of patent or registration of utility model

Ref document number: 5778168

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533